PEA/Polydatin: Anti-Inflammatory and Antioxidant Approach to Counteract DNBS-Induced Colitis

Alessio Filippo Peritore, Ramona D'Amico, Marika Cordaro, Rosalba Siracusa, Roberta Fusco, Enrico Gugliandolo, Tiziana Genovese, Rosalia Crupi, Rosanna Di Paola, Salvatore Cuzzocrea, Daniela Impellizzeri. Antioxidants (Basel). 2021 Mar 16;10(3):464.

Laboratory studyOther animalsWith polydatin (comicronised with ultramicronised PEA)

This study tested palmitoylethanolamide together with polydatin (comicronised with ultramicronised PEA). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.

Design

Laboratory study

Subjects

Mice with colitis induced by intrarectal dinitrobenzene sulfonic acid (4 mg per mouse)

Dose used in the study

Comicronised ultramicronised PEA plus polydatin, 10 mg/kg by mouth (9 mg PEA plus 1 mg polydatin)

Duration

Assessed four days after DNBS

What was measured

Macroscopic and histological colon damage, clinical signs, cytokines, myeloperoxidase, ICAM-1 and P-selectin, and oxidative stress markers (PARP, nitrotyrosine, malondialdehyde); NF-kappa-B and SIRT-1/Nrf2 expression

What the authors reported

Oral PEA/polydatin reduced macroscopic and histological colon damage, neutrophil infiltration, cytokine release, malondialdehyde, nitrotyrosine, PARP, ICAM-1 and P-selectin, while inhibiting NF-kappa-B and increasing SIRT-1 and Nrf2 expression. No numbers are given in the abstract.

Limits of this study

A mouse model of colitis; it cannot show effect in people. One author (Cuzzocrea) is a co-inventor on patents with Epitech Group, which makes the PEA/polydatin formulation; the authors describe those patents as unrelated.

Source

PubMed 33809584 · doi:10.3390/antiox10030464

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.